5 Key Takeaways
-
1
Isarna Therapeutics reported positive phase 2 BETTER trial results for ISTH0036, an antisense therapy targeting TGF-β2.
-
2
The trial involved patients with neovascular age-related macular degeneration and diabetic macular edema.
-
3
Patients receiving ISTH0036 showed stable or improved vision and reduced central retinal thickness.
-
4
The treatment was well tolerated, with no reported increase in intraocular pressure.
-
5
Isarna plans to discuss regulatory pathways for further studies in the U.S. and Europe.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.